Antibacterial Peptide Combinations for Multi-Resistant Bacteria
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack effective means to treat bacterial infections, particularly those caused by multi-resistant bacteria, and fail to provide synergistic antibacterial activity when combining peptides or antibiotics.
Innovation Solution
A peptide comprising 18 to 22 amino acids with a specific sequence (GKKYRRFRWKFKGKLFLFG) and its derivatives, which can be used alone or in combination with other peptides or antibiotics to treat bacterial infections and promote wound healing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to treat bacterial infections, then treatment is provided for common bacterial strains, but they become ineffective against multi-resistant bacteria
Solution Approach 1:
The patent changes the chemical parameter from conventional small-molecule antibiotics to peptide-based antimicrobial agents with specific amino acid sequences (18-22 residues containing cationic and hydrophobic residues). This parameter change enables effectiveness against multi-resistant bacteria while maintaining selective toxicity.
Solution Approach 2:
The invention combines multiple peptides in specific ratios to create composite antimicrobial formulations. This composite approach synergistically enhances activity against resistant strains while reducing individual peptide concentrations needed, thereby overcoming bacterial resistance mechanisms.
2Reliability
If single antibiotics are used for treatment, then simplicity of administration is maintained, but synergistic antibacterial activity is not achieved
Solution Approach 1:
The patent merges multiple peptides into single formulations or combination therapies. This merging creates synergistic effects where the combined antimicrobial activity exceeds the sum of individual components, achieving enhanced reliability while managing complexity through standardized combination protocols.
3Reliability
If existing antimicrobial peptides are used, then some antibacterial activity is achieved, but excellent performance in treating badly healing wounds is not obtained
Solution Approach 1:
The patent optimizes peptide sequences with specific local quality characteristics - particular amino acid compositions (cationic residues like Lysine and Arginine combined with hydrophobic residues like Phenylalanine and Tryptophan) at specific positions. This local quality optimization within the 18-22 residue framework enhances penetration into necrotic wound tissue and binding to bacterial membranes specifically at infection sites.
Solution Approach 2:
The peptide formulations provide multi-functionality by simultaneously exhibiting direct bactericidal activity, promoting wound healing through growth factor stimulation, and reducing inflammation. This universality addresses multiple aspects of wound management with a single therapeutic agent.
Data Source
Figure 1
Figure 2
Figure 3A
AI summary
The present invention relates to a pharmaceutical composition comprising or consisting of a combination of (a) two or more peptides, each peptide consisting of or comprising 17 to 23 amino acids, wherein the amino acids in positions 1 to 23, counted from the N-terminus, are as follows (1) G, S or lacking; (2) C or lacking; (3) K or R; (4) K or R; (5) Y, W or F; (6) K or R; (7) K or R; (8) F, W or L; (9) K or R; (10) K or L or lacking; (11) W, L or F; (12) K or R; (13) F, Y or C; (14) K or R; (15) G or Q; (16) K or R; (17) F, L or W; (18) F or W; (19) F, L or W; (20) W or F; (21) C or lacking; (22) F or G or lacking; (23) G or lacking; or (b) one or more peptides, each peptide consisting of or comprising 17 to 23 amino acids, wherein the amino acids in positions 1 to 23, counted from the N-terminus, are as follows (1) G, S or lacking; (2) C or lacking; (3) K or R; (4) K or R; (5) Y, W or F; (6) K or R; (7) K or R; (8) F, W or L; (9) K or R; (10) K or L or lacking; (11 ) W, L or F; (12) K or R; (13) F, Y or C; (14) K or R; (15) G or Q; (16) K or R; (17) F, L or W; (18) F or W; (19) F, L or W; (20) W or F; (21) C or lacking; (22) F or G or lacking; (23) G or lacking, and one or more antibiotics selected from small organic molecule antibiotics such as ceftriaxone, oxacillin, amoxicillin, amikacin, ciprofloxacin, erythromycin, imipenem and tetracycline, and peptidic antibiotics such as daptomycin and vancomycin.